铁永兰,燕华玲

特应性皮炎（atopic dermatitis，AD）是一种常见的慢性、复发性、炎症性皮肤病，以反复发作和严重瘙痒为主要特征，严重影响患者的生活质量。本文综述了特应性皮炎的治疗进展，包括传统治疗方法如基础治疗、外用药物、系统药物以及物理治疗，以及新兴治疗手段如生物制剂、小分子靶向药物的应用，同时探讨了皮肤微生态调节在未来治疗中的应用，旨在为临床治疗提供全面参考。

特应性皮炎；治疗进展；生物制剂；小分子靶向药物

[1] Chovatiya R.Atopic Dermatitis(Eczema)[J].JAMA,2023,329(3):268. [2] 王建琴.中国特应性皮炎诊疗指南(2020版)解读[J].皮肤性病诊疗学杂志,2020,27(5):3. [3] atayama I,Aihara M,Ohya Y,et al.Japanese guidelines for atopic dermatitis 2017[J].Allergology International Official Journal of the Japanese Society of Allergology,2017,66(2):230-247. [4] Eichenfield L F,Tom W L,Chamlin S L,et al.Guidelines of care for the management of atopic dermatitis[J].Journal of the American Academy of Dermatology,2014,71(2):116-132. [5] Coondoo A,Phiske M,Verma S,et al.Side-effects of topical steroids:A long overdue revisit[J].Indian Dermatology Online Journal, 2014,5(4):416-425. [6] Li A W,Yin E S,Antaya R J.Topical Corticosteroid Phobia in Atopic Dermatitis:A Systematic Review[J].Jama Dermatol,2017,153(10):1-7. [7] Marshall H F,Leung D Y M,Lack G,et al.Topical steroid withdrawal and atopic dermatitis[J].Annals of allergy,asthma,and immunology, 2024(4):132. [8] Gutfreund K.,Bienias W.,Szewczyk A.,Kaszuba A.Topical calcineurin inhibitors in dermatology.Part I:Properties,method and effectiveness of drug use.Postep.Dermatol.I Alergol.2013;30:165–169. [9] Kamata M.,Tada Y.Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence.JID Innov. 2023;3:100195. [10] Lazar M,Zhang A D,Vashi N A.Topical Treatments in Atopic Dermatitis:An Expansive Review[J].Journal of Clinical Medicine, 2024,13(8):19. [11] Yang H.,Wang J.,Zhang X.,Zhang Y.,Qin Z.L.,Wang H.,Luo X.Y.Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis:A Systematic Review and Meta-analysis.JAMA Dermatol.2019;155:585–593. [12] Paller AS,Tom WL,Lebwohl MG,Blumenthal RL,Boguniewicz M,Call RS,et al.Efficacy and safety of crisaborole ointment,a novel,nonsteroidal phosphodiesterase 4(PDE4)inhibitor for the topical treatment of atopic dermatitis(AD)in children and adults.J Am Acad Dermatol.2016,75(3):494-503.e6. [13] Schlessinger J,Shepard JS,Gower R,Su JC,Lynde C,Cha A,et al.CARE 1 Investigators.Safety,Effectiveness,and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis:A Phase IV Open-Label Study(CrisADe CARE 1). Am J Clin Dermatol.2020 Apr;21(2):275-284. [14] Schmitt J,Buske-Kirschbaum A,Tesch F,et al.Increased attention‐deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use[J].Allergy,2018. [15] He A,Feldman S R,Fleischer A B.An assessment of the use of antihistamines in the management of atopic dermatitis[J].Journal of the American Academy of Dermatology,2018,79(1):92–96. [16] Kim J E,Shin J M,Ko J Y,et al.Importance of concomitant topical therapy in moderate‐to‐severe atopic dermatitis treated with cyclosporine[J].Dermatologic Therapy,2016,29(2):120-125. [17] Gerbens L A A,Hamann S A S,Brouwer M W D,et al.Methotrexate and azathioprine for severe atopic dermatitis:a 5-year follow-up study of a randomized controlled trial[J].British Journal of Dermatology,2018,178(6):e437-e437. [18] Deva M,Netting M J,Weidinger,JemmaBrand,RolandLoh,Richard K.S.Vale,Sandra L.A systematic review of guidelines for the management of atopic dermatitis in children[J].world allergy organization journal,2024,17(12). [19] B,Wüthrich,G,et al.Letter to the Editor:Consensus-based European guidelines for treatment of atopic eczema(atopic dermatitis)in adults and children:part II.[J].Journal of the European Academy of Dermatology&Venereology Jeadv,2019,32(6):850–878. [20] Lee J H,Kim J E,Park G H,et al.Consensus Update for Systemic Treatment of Atopic Dermatitis.[J].Korean Dermatological Association and The Korean Society for Investigative Dermatology,2021(6). [21] Wollenberg A,Christen-Zäch S,Taieb A,et al.ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.J Eur Acad Dermatol Venereol.2020;34(12):2717-2744. [22] Gürel,Deniz lgün,Soyer Z,Ahiner M M.Systemic treatments in atopic dermatitis in children[J].Turkish Journal of Pediatrics, 2023,65(6). [23] Shweta S,Milind P.New Insights and Treatments in Atopic Dermatitis[J].Immunology and allergy clinics of North America, 2021, 2021,41(4):653-665. [24] Yim H J,Jean T,Ong P Y.Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis[J].Current Allergy&Asthma Reports,2024,24(5). [25] Blauvelt A,de Bruin-Weller M,Gooderham M,et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids(LIBERTY AD CHRONOS):a 1-year,randomised,double-blinded,placebo-controlled,phase 3 trial.Lancet.2017 Jun;389(10086):2287–2303. [26] Nevid M,Boguniewicz M.Current and Emerging Biologics for Atopic Dermatitis.Immunol Allergy Clin North Am.2024 Nov; 44(4):577-594. [27] Paller AS,Siegfried EC,Thac ID,et al.Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis:A randomized,double-blinded,placebo-controlled phase 3 trial.J Am Acad Dermatol.2020; 83(5):1282-1293. [28] Teixeira C,Yilmaz O,Bernardo D,et al.IL-13 inhibition in the treatment of atopic dermatitis–new and emerging biologic agents[J]. Journal of International Medical Research,2024,52(11). [29] Bernardo D,Bieber T,Torres T.Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis[J].American Journal of Clinical Dermatology,2023,24(5):753-764. [30] E.L.Simpson,M.Gooderham,A.Wollenberg,et al.Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis:A Randomized Clinical Trial(ADhere).JAMA Dermatol.2023 Feb 1;159(2):182-191. [31] D'Auria E,Indolfi C,Acunzo M,et al.Biologics and small molecules:the re-evolution in the treatment of atopic dermatitis in children and adolescents.Current state of the art and future perspectives[J].Expert Rev Clin Immunol.2025,21(4):493-505. [32] Kabashima K,Matsumura T,Komazaki H,et al.Trial of nemolizumab and topical agents for atopic dermatitis with pruritus.N Engl J Med.2020,383(2):141–150. [33] Sidbury R,Alpizar S,Laquer V,et al.Pharmacokinetics,safety,efficacy,and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents.Dermatol Ther(Heidelb).2022,12(3):631–642. [34] E.L.Simpson,R.Sinclair,S.Forman,et al.Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis(JADE MONO-1):a multicentre,double-blind,randomised,placebo-controlled,phase 3 trial.Lancet.2020 Jul 25;396(10246):255-266. [35] Silverberg J I,Simpson E L,Thyssen J P,et al.Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis:A Randomized Clinical Trial.[J].American Medical Association,2020,156(8):863-873. [36] Rademaker M,Agnew K,Andrews M,et al.Managing atopic dermatitis with systemic therapies in adults and adolescents:An Australian/New Zealand narrative.[J].Australas J Dermatol,2020(1). [37] Fang Z,Li L,Zhang H,et al.Gut Microbiota,Probiotics,and Their Interactions in Prevention and Treatment of Atopic Dermatitis:A Review[J].Frontiers in Immunology,2021,12:720393. [38] Huang R,Ning H,Shen M,Li J,Zhang J,Chen X.Probiotics for the Treatment of Atopic Dermatitis in Children:A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Front Cell Infect Microbiol.2017,6(7):392.

点击下载PDF